Systemic lupus erythematosus+1
Not recruitingEvaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion
Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion
- Disease:Systemic lupus erythematosusCutaneous lupus erythematosus
- Substances:Enpatoran
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Enpatoran
- Sponsor:Merck Healthcare KGaA














